Starpharma dendrimer nanotech boosts cancer fight; Hemispherx launches injectable wart treatment in Argentina;

> Australia's Starpharma says a recent clinical study proved the docetaxel chemotherapy drug formulated with its dendrimer nanotechnology was more effective at tumor treatment than docetaxel on its own. Story

> Celator Pharmaceuticals obtained orphan drug status in Europe for CPX-351, its liposomal two-drug combo to treat acute myeloid leukemia. The drug uses liposome injection for drug delivery to maintain the proper ratio of both drugs after injection. Release

> Hemispherx Biopharma has gained regulatory approval to market its Alferon N treatment for genital warts in Argentina. GP Pharm will market the drug, an injectable formulation of natural alpha interferon, under the name Naturaferon. The drug is already approved in the U.S. Release

> SeekingAlpha bets that two biotechs focused on transdermal drug delivery will be generating some post-approval buzz this year: Apricus Biosciences, with its NexACT transdermal drug delivery system for a variety of indications, and BioSante, a biotech focused on oncology and sexual health. Story

> Generex Biotechnology raised $2 million to help fund general operations. The company is developing technology that would allow drugs, in liquid form, to be absorbed by the lining of the inner mouth. Release

Suggested Articles

Takeda forged a feasibility pact to see whether it could pair a plasma-based therapy with Elektrofi's microparticle delivery tech.

RNA nanoparticles can squeeze into tumors and exit swiftly through the kidney, perfect for targeted delivery of cancer drugs, an OSU team says.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.